

| <b>NDC</b>    | <b>Drug Product Description</b>                 | <b>Introduction to Market</b> | <b>WAC at Introduction</b> |
|---------------|---|-------------------------------|----------------------------|
| 00078-1161-47 | Mekinist (trametinib) for oral solution         | Thursday, May 25, 2023        | \$1,548.98                 |
| 00078-1154-21 | Tafinlar (dabrafenib) tablets for oral solution | Thursday, May 25, 2023        | \$3,663.27                 |

**Estimated volume of patients who may be prescribed drug in 2023**

226

226

**Breakthrough therapy designation? (Y/N)    Priority Review? (Y/N)**

Y  
Y

Y  
Y

**Date and price of acquisition if the drug was not developed by the manufacturer else | A descrip**

N/A

Novartis cc

N/A

Novartis cc

onsidered many factors in determining the price of Mekinist. Tafinlar + Mekinist, the worldwide targeted therapy le  
onsidered many factors in determining the price of Tafinlar. Tafinlar + Mekinist, the worldwide targeted therapy le

ader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic indication for ac  
ader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic indication for adl

Adult and pediatric patients with solid tumors that have a BRAF V600E mutation. We priced in parity to other brands.  
Adult and pediatric patients with solid tumors that have a BRAF V600E mutation. We priced in parity to other brands.

ded treatments in this therapeutic area and are focused on access to Mekinist for this patient population.  
ed treatments in this therapeutic area and are focused on access to Tafinlar for this patient population.